JONATHAN GOODWIN: Open Payments
NPI 1336738293 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,783 in 58 payments from 20 companies in 2025. Trend: 2023 $1,472 · 2024 $2,248 · 2025 $1,783
Food & beverage: $1,749Education: $34
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 12 | $398 |
| AstraZeneca Pharmaceuticals LP | 9 | $371 |
| Genentech, Inc. | 1 | $150 |
| CSL Behring | 10 | $145 |
| Blueprint Medicines Corporation | 2 | $144 |
| Genentech USA, Inc. | 3 | $143 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $81 |
| Amgen Inc. | 2 | $52 |
| ABBVIE INC. | 2 | $49 |
| Optinose US, Inc. | 2 | $41 |
Products named: DUPIXENT, Xolair, TEZSPIRE, AYVAKIT, FASENRA, NEFFY, Haegarda, Andembry.
Industry payments across OK — which companies pay providers there.
